APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Frovatriptan Succinate Tablets

Frovatriptan Succinate Tablets are immediate-release, film-coated oral tablets containing frovatriptan as the succinate monohydrate salt for the acute treatment of migraine with or without aura in adults; they are not intended for prophylaxis. The clinical strength is standardized to 2.5 mg frovatriptan free base per tablet, achieved by 3.91 mg frovatriptan succinate (monohydrate) as the active pharmaceutical ingredient (API). The succinate salt is selected for robust crystallinity, aqueous processability, and control of polymorphism/hydrate state, enabling consistent compressibility and dissolution. Typical excipients in a well-engineered formulation are a diluent (e.g., lactose monohydrate or anhydrous lactose) to achieve tablet mass and API dispersion, a direct-compression filler (microcrystalline cellulose) for tablet strength, a superdisintegrant (sodium starch glycolate or croscarmellose sodium) to ensure rapid breakup, a glidant (colloidal silicon dioxide) to stabilize flow, and a lubricant (magnesium stearate) controlled at low levels to avoid hydrophobic slowdown of dissolution; the film coat is commonly hypromellose-based with a plasticizer and opacifier to improve swallowability, light protection, and handling.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Frovatriptan Succinate Tablets are immediate-release, film-coated oral tablets containing frovatriptan as the succinate monohydrate salt for the acute treatment of migraine with or without aura in adults; they are not intended for prophylaxis. The clinical strength is standardized to 2.5 mg frovatriptan free base per tablet, achieved by 3.91 mg frovatriptan succinate (monohydrate) as the active pharmaceutical ingredient (API). The succinate salt is selected for robust crystallinity, aqueous processability, and control of polymorphism/hydrate state, enabling consistent compressibility and dissolution. Typical excipients in a well-engineered formulation are a diluent (e.g., lactose monohydrate or anhydrous lactose) to achieve tablet mass and API dispersion, a direct-compression filler (microcrystalline cellulose) for tablet strength, a superdisintegrant (sodium starch glycolate or croscarmellose sodium) to ensure rapid breakup, a glidant (colloidal silicon dioxide) to stabilize flow, and a lubricant (magnesium stearate) controlled at low levels to avoid hydrophobic slowdown of dissolution; the film coat is commonly hypromellose-based with a plasticizer and opacifier to improve swallowability, light protection, and handling.

Mechanistically, frovatriptan is a high-affinity 5-hydroxytryptamine (serotonin) 1B/1D receptor agonist. Therapeutic benefit in migraine derives from three convergent actions within the trigeminovascular system: selective constriction of dilated extracerebral intracranial arteries via 5-HT1B activation, inhibition of neuropeptide (e.g., CGRP) release from trigeminal terminals via 5-HT1D activation, and suppression of nociceptive transmission in central trigeminal pathways. Frovatriptan exhibits minimal activity at non-target serotonergic subtypes and negligible affinity for adrenergic, dopaminergic, or histaminergic receptors at therapeutic exposures, contributing to a clean pharmacodynamic profile. A distinguishing clinical pharmacology feature is its long terminal half-life (on the order of a day), which underpins a lower 24-hour headache recurrence rate compared with shorter-acting triptans.

Key pharmacokinetics after a single 2.5 mg oral dose are consistent and predictable: absorption is complete with peak plasma concentrations typically reached about 2–4 hours post-dose; absolute oral bioavailability is modest (roughly one-quarter), reflecting first-pass metabolism rather than poor permeability. Plasma protein binding is low (≈15%), and a notable blood-to-plasma partitioning (~2:1) indicates red-cell association that effectively expands distribution. Elimination is driven by hepatic oxidative metabolism predominantly through CYP1A2 to hydroxylated and N-dealkylated species with much lower 5-HT1B/1D affinity than parent; renal excretion contributes to clearance but is not the dominant route. Food does not meaningfully alter the extent of absorption; at most it may delay t_max slightly without clinical consequence. Sex-related exposure differences are observed (higher systemic exposure in females), but dose adjustment is not required in routine practice. Severe hepatic impairment can increase exposure and is a context for caution or avoidance; mild-to-moderate renal impairment has limited effect given the drug’s distribution and metabolic clearance characteristics.

Clinical use is straightforward: 2.5 mg orally at onset of migraine; if needed, a second 2.5 mg may be taken after at least 2 hours, with a maximum of 7.5 mg in 24 hours. Frovatriptan is contraindicated in ischemic heart disease, coronary vasospasm (Prinzmetal angina), history of stroke/TIA, uncontrolled hypertension, and within 24 hours of ergot-type migraine medications or another triptan. Serotonergic co-medication (SSRIs/SNRIs, linezolid, etc.) warrants vigilance for serotonin-toxicity symptoms. Clinically relevant pharmacokinetic interactions primarily involve strong CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin), which can raise exposure; conversely, potent CYP1A2 induction (e.g., heavy cigarette smoking) may reduce exposure and effect. As with all triptans, hemiplegic or basilar/brainstem migraine phenotypes are outside the labeled use.

From a CMC and manufacturing standpoint, the API is obtained as the succinate monohydrate with a controlled polymorphic/hydrate form verified by XRPD and water content (Karl Fischer) release tests. A modern, impurity-conscious synthesis typically constructs the indole/tetrahydrocarbazine core, installs the dimethylsulfonamide and side-chain functionality under conditions that minimize formation of sulfonate esters or other potential mutagenic species, and then performs salt formation with stoichiometric succinic acid in an alcohol–water system. Tight control of residual solvents (per ICH Q3C), elemental impurities (Q3D), and genotoxic impurities (M7) is expected, with specification limits justified by toxicological assessment and process capability. Particle-size distribution (e.g., D90 in the low-to-mid tens of micrometers) is set to balance blend homogeneity with dissolution performance; excessive micronization is avoided to prevent cohesion and flow problems.

Tablet manufacture uses either direct compression (preferred for simplicity and fewer moisture/heat stresses) or a low-shear wet-granulation step if the chosen excipient system needs granule strengthening. Critical process parameters are blend uniformity (assayed by stratified sampling and near-IR where available), lubricant blending time (kept minimal to avoid over-lubrication that can impair disintegration), compaction force (to meet hardness/friability targets without capping), and coat application weight gain (for mechanical integrity and appearance while preserving immediate release). A well-designed quality target product profile specifies rapid disintegration (<15 min) and rapid dissolution in acidic medium (e.g., ≥80% released within 30 min in 0.1 N HCl under paddle conditions), aligned with the reference product to support bioequivalence. Release testing covers identification (IR/UV and chromatographic), assay and content uniformity (HPLC), related substances (stability-indicating HPLC with qualified reporting/qualification thresholds), dissolution, water content, and microbial limits as appropriate for a non-sterile solid. Stability programs follow ICH climatic zone-appropriate conditions to set shelf life; packaging is moisture-protective (alu-alu blisters or HDPE bottles with desiccant), given the hydrate form’s sensitivity to low-humidity environments that can shift water content and subtly affect dissolution.

Bioequivalence for generic products adheres to standard single-dose, crossover studies in healthy adults with fasting conditions, comparing C_max and AUC (0-t and 0-∞) within the conventional 80–125% confidence intervals; a supportive fed study may be required to bracket food effects depending on jurisdiction. Comparative dissolution across at least three media (acidic, intermediate pH, and buffer) and multiple paddle speeds is used as an in-vitro surrogate to ensure formulation sameness. In vitro–in vivo correlation is not typically established for immediate-release triptans, so dissolution method robustness and discriminatory power carry added weight in lifecycle controls.

Risk management focuses on class-specific vascular events, medication-overuse headache with frequent use, and rare hypersensitivity. Patient-level good practice emphasizes using the earliest effective dose at attack onset, respecting 24-hour maxima, avoiding duplicate triptan/ergot therapy windows, and screening for cardiovascular disease before first use in at-risk populations. At the product level, a disciplined control strategy—from route design that avoids genotoxic liabilities through validated analytics and stability-indicating methods—ensures a reproducible, high-quality tablet whose clinical performance matches the reference while maintaining manufacturing robustness over the product lifecycle.

Selected research

Industry Growth & Trends

Global Frovatriptan Succinate Tablets Industry Growth and Trends Forecast to 2032

Report ID 173993220121 December 2025112 pages

Choose your research edition.

Industry ResearchFrovatriptan Succinate Tablets Industry Research Report 2026136 pages · $2,950 USDIndustry Growth & TrendsGlobal Frovatriptan Succinate Tablets Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Frovatriptan Succinate Tablets Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Frovatriptan Succinate Tablets Market Outlook and Growth Opportunities 2026208 pages · $4,250 USDMarket Analysis & ForecastGlobal Frovatriptan Succinate Tablets Market Analysis and Forecast 2026-2032200 pages · $4,950 USD

Market perspective

Frovatriptan Succinate Tablets are immediate-release, film-coated oral tablets containing frovatriptan as the succinate monohydrate salt for the acute treatment of migraine with or without aura in adults; they are not intended for prophylaxis. The clinical strength is standardized to 2.5 mg frovatriptan free base per tablet, achieved by 3.91 mg frovatriptan succinate (monohydrate) as the active pharmaceutical ingredient (API). The succinate salt is selected for robust crystallinity, aqueous processability, and control of polymorphism/hydrate state, enabling consistent compressibility and dissolution. Typical excipients in a well-engineered formulation are a diluent (e.g., lactose monohydrate or anhydrous lactose) to achieve tablet mass and API dispersion, a direct-compression filler (microcrystalline cellulose) for tablet strength, a superdisintegrant (sodium starch glycolate or croscarmellose sodium) to ensure rapid breakup, a glidant (colloidal silicon dioxide) to stabilize flow, and a lubricant (magnesium stearate) controlled at low levels to avoid hydrophobic slowdown of dissolution; the film coat is commonly hypromellose-based with a plasticizer and opacifier to improve swallowability, light protection, and handling.

Mechanistically, frovatriptan is a high-affinity 5-hydroxytryptamine (serotonin) 1B/1D receptor agonist. Therapeutic benefit in migraine derives from three convergent actions within the trigeminovascular system: selective constriction of dilated extracerebral intracranial arteries via 5-HT1B activation, inhibition of neuropeptide (e.g., CGRP) release from trigeminal terminals via 5-HT1D activation, and suppression of nociceptive transmission in central trigeminal pathways. Frovatriptan exhibits minimal activity at non-target serotonergic subtypes and negligible affinity for adrenergic, dopaminergic, or histaminergic receptors at therapeutic exposures, contributing to a clean pharmacodynamic profile. A distinguishing clinical pharmacology feature is its long terminal half-life (on the order of a day), which underpins a lower 24-hour headache recurrence rate compared with shorter-acting triptans.

Key pharmacokinetics after a single 2.5 mg oral dose are consistent and predictable: absorption is complete with peak plasma concentrations typically reached about 2–4 hours post-dose; absolute oral bioavailability is modest (roughly one-quarter), reflecting first-pass metabolism rather than poor permeability. Plasma protein binding is low (≈15%), and a notable blood-to-plasma partitioning (~2:1) indicates red-cell association that effectively expands distribution. Elimination is driven by hepatic oxidative metabolism predominantly through CYP1A2 to hydroxylated and N-dealkylated species with much lower 5-HT1B/1D affinity than parent; renal excretion contributes to clearance but is not the dominant route. Food does not meaningfully alter the extent of absorption; at most it may delay t_max slightly without clinical consequence. Sex-related exposure differences are observed (higher systemic exposure in females), but dose adjustment is not required in routine practice. Severe hepatic impairment can increase exposure and is a context for caution or avoidance; mild-to-moderate renal impairment has limited effect given the drug’s distribution and metabolic clearance characteristics.

Read the full market overview

Clinical use is straightforward: 2.5 mg orally at onset of migraine; if needed, a second 2.5 mg may be taken after at least 2 hours, with a maximum of 7.5 mg in 24 hours. Frovatriptan is contraindicated in ischemic heart disease, coronary vasospasm (Prinzmetal angina), history of stroke/TIA, uncontrolled hypertension, and within 24 hours of ergot-type migraine medications or another triptan. Serotonergic co-medication (SSRIs/SNRIs, linezolid, etc.) warrants vigilance for serotonin-toxicity symptoms. Clinically relevant pharmacokinetic interactions primarily involve strong CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin), which can raise exposure; conversely, potent CYP1A2 induction (e.g., heavy cigarette smoking) may reduce exposure and effect. As with all triptans, hemiplegic or basilar/brainstem migraine phenotypes are outside the labeled use.

From a CMC and manufacturing standpoint, the API is obtained as the succinate monohydrate with a controlled polymorphic/hydrate form verified by XRPD and water content (Karl Fischer) release tests. A modern, impurity-conscious synthesis typically constructs the indole/tetrahydrocarbazine core, installs the dimethylsulfonamide and side-chain functionality under conditions that minimize formation of sulfonate esters or other potential mutagenic species, and then performs salt formation with stoichiometric succinic acid in an alcohol–water system. Tight control of residual solvents (per ICH Q3C), elemental impurities (Q3D), and genotoxic impurities (M7) is expected, with specification limits justified by toxicological assessment and process capability. Particle-size distribution (e.g., D90 in the low-to-mid tens of micrometers) is set to balance blend homogeneity with dissolution performance; excessive micronization is avoided to prevent cohesion and flow problems.

Tablet manufacture uses either direct compression (preferred for simplicity and fewer moisture/heat stresses) or a low-shear wet-granulation step if the chosen excipient system needs granule strengthening. Critical process parameters are blend uniformity (assayed by stratified sampling and near-IR where available), lubricant blending time (kept minimal to avoid over-lubrication that can impair disintegration), compaction force (to meet hardness/friability targets without capping), and coat application weight gain (for mechanical integrity and appearance while preserving immediate release). A well-designed quality target product profile specifies rapid disintegration (<15 min) and rapid dissolution in acidic medium (e.g., ≥80% released within 30 min in 0.1 N HCl under paddle conditions), aligned with the reference product to support bioequivalence. Release testing covers identification (IR/UV and chromatographic), assay and content uniformity (HPLC), related substances (stability-indicating HPLC with qualified reporting/qualification thresholds), dissolution, water content, and microbial limits as appropriate for a non-sterile solid. Stability programs follow ICH climatic zone-appropriate conditions to set shelf life; packaging is moisture-protective (alu-alu blisters or HDPE bottles with desiccant), given the hydrate form’s sensitivity to low-humidity environments that can shift water content and subtly affect dissolution.

Bioequivalence for generic products adheres to standard single-dose, crossover studies in healthy adults with fasting conditions, comparing C_max and AUC (0-t and 0-∞) within the conventional 80–125% confidence intervals; a supportive fed study may be required to bracket food effects depending on jurisdiction. Comparative dissolution across at least three media (acidic, intermediate pH, and buffer) and multiple paddle speeds is used as an in-vitro surrogate to ensure formulation sameness. In vitro–in vivo correlation is not typically established for immediate-release triptans, so dissolution method robustness and discriminatory power carry added weight in lifecycle controls.

Risk management focuses on class-specific vascular events, medication-overuse headache with frequent use, and rare hypersensitivity. Patient-level good practice emphasizes using the earliest effective dose at attack onset, respecting 24-hour maxima, avoiding duplicate triptan/ergot therapy windows, and screening for cardiovascular disease before first use in at-risk populations. At the product level, a disciplined control strategy—from route design that avoids genotoxic liabilities through validated analytics and stability-indicating methods—ensures a reproducible, high-quality tablet whose clinical performance matches the reference while maintaining manufacturing robustness over the product lifecycle.

The global Frovatriptan Succinate Tablets market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Frovatriptan Succinate Tablets is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Frovatriptan Succinate Tablets is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

The Asia Pacific market for Frovatriptan Succinate Tablets is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Frovatriptan Succinate Tablets include Viatris, Teva, Endo Pharmaceuticals, Chia Tai Tianqing, HitGen, Accord（Intas）, Amneal Pharmaceuticals, Milpharm (Aurobindo) and Dr. Reddy’s, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Frovatriptan Succinate Tablets market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Frovatriptan Succinate Tablets market size, estimates, and forecasts are presented in terms of sales volume (k tablets) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Frovatriptan Succinate Tablets market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Frovatriptan Succinate Tablets.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Frovatriptan Succinate Tablets market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Frovatriptan Succinate Tablets Market by Company

Viatris

Teva

Endo Pharmaceuticals

Chia Tai Tianqing

HitGen

Accord（Intas）

Amneal Pharmaceuticals

Milpharm (Aurobindo)

Dr. Reddy’s

Sandoz

Zydus

Sun Pharma

Apotex

Clydesdale Pharma

Glenmark Pharmaceuticals

Ingenus Pharmaceutical

Frovatriptan Succinate Tablets Segment by Type

Originator (RMP)

Originator-Licensed Brand

Authorized Generic (AG)

Conventional Generic

Frovatriptan Succinate Tablets Segment by Application

Hospital and Clinic

Retail Pharmacies

Other

Frovatriptan Succinate Tablets Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Frovatriptan Succinate Tablets market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Frovatriptan Succinate Tablets and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Frovatriptan Succinate Tablets.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Frovatriptan Succinate Tablets manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Frovatriptan Succinate Tablets in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Originator (RMP) Table 2. Major Company of Originator-Licensed Brand Table 3. Major Company of Authorized Generic (AG) Table 4. Major Company of Conventional Generic Table 5. Global Frovatriptan Succinate Tablets Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 6. Global Frovatriptan Succinate Tablets Sales by Type (2021-2026) & (k tablets) Table 7. Global Frovatriptan Succinate Tablets Sales Market Share in Volume by Type (2021-2026) Table 8. Global Frovatriptan Succinate Tablets Sales by Type (2021-2026) & (US$ Million) Table 9. Global Frovatriptan Succinate Tablets Sales Market Share in Value by Type (2021-2026) Table 10. Global Frovatriptan Succinate Tablets Price by Type (2021-2026) & (USD/k tablets) Table 11. Global Frovatriptan Succinate Tablets Sales by Type (2027-2032) & (k tablets) Table 12. Global Frovatriptan Succinate Tablets Sales Market Share in Volume by Type (2027-2032) Table 13. Global Frovatriptan Succinate Tablets Sales by Type (2027-2032) & (US$ Million) Table 14. Global Frovatriptan Succinate Tablets Sales Market Share in Value by Type (2027-2032) Table 15. Global Frovatriptan Succinate Tablets Price by Type (2027-2032) & (USD/k tablets) Table 16. North America Frovatriptan Succinate Tablets Sales by Type (2021-2026) & (k tablets) Table 17. North America Frovatriptan Succinate Tablets Sales by Type (2021-2026) & (US$ Million) Table 18. Europe Frovatriptan Succinate Tablets Sales by Type (2021-2026) & (k tablets) Table 19. Europe Frovatriptan Succinate Tablets Sales by Type (2021-2026) & (US$ Million) Table 20. Asia-Pacific Frovatriptan Succinate Tablets Sales by Type (2021-2026) & (k tablets) Table 21. Asia-Pacific Frovatriptan Succinate Tablets Sales by Type (2021-2026) & (US$ Million) Table 22. Latin America Frovatriptan Succinate Tablets Sales by Type (2021-2026) & (k tablets) Table 23. Latin America Frovatriptan Succinate Tablets Sales by Type (2021-2026) & (US$ Million) Table 24. Middle East and Africa Frovatriptan Succinate Tablets Sales by Type (2021-2026) & (k tablets) Table 25. Middle East and Africa Frovatriptan Succinate Tablets Sales by Type (2021-2026) & (US$ Million) Table 26. Frovatriptan Succinate Tablets Industry Trends Table 27. Frovatriptan Succinate Tablets Industry Drivers Table 28. Frovatriptan Succinate Tablets Industry Opportunities and Challenges Table 29. Frovatriptan Succinate Tablets Industry Restraints Table 30. Global Frovatriptan Succinate Tablets Sales Revenue by Company (US$ Million) & (2021-2026) Table 31. Global Frovatriptan Succinate Tablets Revenue Market Share by Company (2021-2026) Table 32. Global Frovatriptan Succinate Tablets Sales by Company (2021-2026) & (k tablets) Table 33. Global Frovatriptan Succinate Tablets Sales Share by Company (2021-2026) Table 34. Global Frovatriptan Succinate Tablets Market Price by Company (2021-2026) & (USD/k tablets) Table 35. Global Frovatriptan Succinate Tablets Industry Company Ranking, 2024 VS 2025 VS 2026 Table 36. Global Frovatriptan Succinate Tablets Major Company Production Sites and Headquarters Table 37. Global Frovatriptan Succinate Tablets Company, Product Type & Application Table 38. Global Frovatriptan Succinate Tablets Company Establishment Date Table 39. Global Company Market Concentration Ratio (CR5 and HHI) Table 40. Global Frovatriptan Succinate Tablets by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 41. Global Frovatriptan Succinate Tablets Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 42. Global Frovatriptan Succinate Tablets Sales by Region (2021-2026) & (k tablets) Table 43. Global Frovatriptan Succinate Tablets Sales Market Share in Volume by Region (2021-2026) Table 44. Global Frovatriptan Succinate Tablets Sales by Region (2021-2026) & (US$ Million) Table 45. Global Frovatriptan Succinate Tablets Sales Market Share in Value by Region (2021-2026) Table 46. Global Frovatriptan Succinate Tablets Sales (k tablets), Value (US$ Million), Price (USD/k tablets) and Gross Margin (2021-2026) Table 47. Global Frovatriptan Succinate Tablets Sales by Region (2027-2032) & (k tablets) Table 48. Global Frovatriptan Succinate Tablets Sales Market Share in Volume by Region (2027-2032) Table 49. Global Frovatriptan Succinate Tablets Sales by Region (2027-2032) & (US$ Million) Table 50. Global Frovatriptan Succinate Tablets Sales Market Share in Value by Region (2027-2032) Table 51. Global Frovatriptan Succinate Tablets Sales (k tablets), Value (US$ Million), Price (USD/k tablets) and Gross Margin (2027-2032) Table 52. Global Frovatriptan Succinate Tablets Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 53. Global Frovatriptan Succinate Tablets Sales by Application (2021-2026) & (k tablets) Table 54. Global Frovatriptan Succinate Tablets Sales Market Share in Volume by Application (2021-2026) Table 55. Global Frovatriptan Succinate Tablets Sales by Application (2021-2026) & (US$ Million) Table 56. Global Frovatriptan Succinate Tablets Sales Market Share in Value by Application (2021-2026) Table 57. Global Frovatriptan Succinate Tablets Price by Application (2021-2026) & (USD/k tablets) Table 58. Global Frovatriptan Succinate Tablets Sales by Application (2027-2032) & (k tablets) Table 59. Global Frovatriptan Succinate Tablets Sales Market Share in Volume by Application (2027-2032) Table 60. Global Frovatriptan Succinate Tablets Sales by Application (2027-2032) & (US$ Million) Table 61. Global Frovatriptan Succinate Tablets Sales Market Share in Value by Application (2027-2032) Table 62. Global Frovatriptan Succinate Tablets Price by Application (2027-2032) & (USD/k tablets) Table 63. North America Frovatriptan Succinate Tablets Sales by Application (2021-2026) & (k tablets) Table 64. North America Frovatriptan Succinate Tablets Sales by Application (2021-2026) & (US$ Million) Table 65. Europe Frovatriptan Succinate Tablets Sales by Application (2021-2026) & (k tablets) Table 66. Europe Frovatriptan Succinate Tablets Sales by Application (2021-2026) & (US$ Million) Table 67. Asia-Pacific Frovatriptan Succinate Tablets Sales by Application (2021-2026) & (k tablets) Table 68. Asia-Pacific Frovatriptan Succinate Tablets Sales by Application (2021-2026) & (US$ Million) Table 69. Latin America Frovatriptan Succinate Tablets Sales by Application (2021-2026) & (k tablets) Table 70. Latin America Frovatriptan Succinate Tablets Sales by Application (2021-2026) & (US$ Million) Table 71. Middle East and Africa Frovatriptan Succinate Tablets Sales by Application (2021-2026) & (k tablets) Table 72. Middle East and Africa Frovatriptan Succinate Tablets Sales by Application (2021-2026) & (US$ Million) Table 73. Viatris Company Information Table 74. Viatris Business Overview Table 75. Viatris Frovatriptan Succinate Tablets Sales (k tablets), Revenue (US$ Million), Price (USD/k tablets) and Gross Margin (2021-2026) Table 76. Viatris Frovatriptan Succinate Tablets Product Portfolio Table 77. Viatris Recent Development Table 78. Teva Company Information Table 79. Teva Business Overview Table 80. Teva Frovatriptan Succinate Tablets Sales (k tablets), Revenue (US$ Million), Price (USD/k tablets) and Gross Margin (2021-2026) Table 81. Teva Frovatriptan Succinate Tablets Product Portfolio Table 82. Teva Recent Development Table 83. Endo Pharmaceuticals Company Information Table 84. Endo Pharmaceuticals Business Overview Table 85. Endo Pharmaceuticals Frovatriptan Succinate Tablets Sales (k tablets), Revenue (US$ Million), Price (USD/k tablets) and Gross Margin (2021-2026) Table 86. Endo Pharmaceuticals Frovatriptan Succinate Tablets Product Portfolio Table 87. Endo Pharmaceuticals Recent Development Table 88. Chia Tai Tianqing Company Information Table 89. Chia Tai Tianqing Business Overview Table 90. Chia Tai Tianqing Frovatriptan Succinate Tablets Sales (k tablets), Revenue (US$ Million), Price (USD/k tablets) and Gross Margin (2021-2026) Table 91. Chia Tai Tianqing Frovatriptan Succinate Tablets Product Portfolio Table 92. Chia Tai Tianqing Recent Development Table 93. HitGen Company Information Table 94. HitGen Business Overview Table 95. HitGen Frovatriptan Succinate Tablets Sales (k tablets), Revenue (US$ Million), Price (USD/k tablets) and Gross Margin (2021-2026) Table 96. HitGen Frovatriptan Succinate Tablets Product Portfolio Table 97. HitGen Recent Development Table 98. Accord（Intas） Company Information Table 99. Accord（Intas） Business Overview Table 100. Accord（Intas） Frovatriptan Succinate Tablets Sales (k tablets), Revenue (US$ Million), Price (USD/k tablets) and Gross Margin (2021-2026) Table 101. Accord（Intas） Frovatriptan Succinate Tablets Product Portfolio Table 102. Accord（Intas） Recent Development Table 103. Amneal Pharmaceuticals Company Information Table 104. Amneal Pharmaceuticals Business Overview Table 105. Amneal Pharmaceuticals Frovatriptan Succinate Tablets Sales (k tablets), Revenue (US$ Million), Price (USD/k tablets) and Gross Margin (2021-2026) Table 106. Amneal Pharmaceuticals Frovatriptan Succinate Tablets Product Portfolio Table 107. Amneal Pharmaceuticals Recent Development Table 108. Milpharm (Aurobindo) Company Information Table 109. Milpharm (Aurobindo) Business Overview Table 110. Milpharm (Aurobindo) Frovatriptan Succinate Tablets Sales (k tablets), Revenue (US$ Million), Price (USD/k tablets) and Gross Margin (2021-2026) Table 111. Milpharm (Aurobindo) Frovatriptan Succinate Tablets Product Portfolio Table 112. Milpharm (Aurobindo) Recent Development Table 113. Dr. Reddy’s Company Information Table 114. Dr. Reddy’s Business Overview Table 115. Dr. Reddy’s Frovatriptan Succinate Tablets Sales (k tablets), Revenue (US$ Million), Price (USD/k tablets) and Gross Margin (2021-2026) Table 116. Dr. Reddy’s Frovatriptan Succinate Tablets Product Portfolio Table 117. Dr. Reddy’s Recent Development Table 118. Sandoz Company Information Table 119. Sandoz Business Overview Table 120. Sandoz Frovatriptan Succinate Tablets Sales (k tablets), Revenue (US$ Million), Price (USD/k tablets) and Gross Margin (2021-2026) Table 121. Sandoz Frovatriptan Succinate Tablets Product Portfolio Table 122. Sandoz Recent Development Table 123. Zydus Company Information Table 124. Zydus Business Overview Table 125. Zydus Frovatriptan Succinate Tablets Sales (k tablets), Revenue (US$ Million), Price (USD/k tablets) and Gross Margin (2021-2026) Table 126. Zydus Frovatriptan Succinate Tablets Product Portfolio Table 127. Zydus Recent Development Table 128. Sun Pharma Company Information Table 129. Sun Pharma Business Overview Table 130. Sun Pharma Frovatriptan Succinate Tablets Sales (k tablets), Revenue (US$ Million), Price (USD/k tablets) and Gross Margin (2021-2026) Table 131. Sun Pharma Frovatriptan Succinate Tablets Product Portfolio Table 132. Sun Pharma Recent Development Table 133. Apotex Company Information Table 134. Apotex Business Overview Table 135. Apotex Frovatriptan Succinate Tablets Sales (k tablets), Revenue (US$ Million), Price (USD/k tablets) and Gross Margin (2021-2026) Table 136. Apotex Frovatriptan Succinate Tablets Product Portfolio Table 137. Apotex Recent Development Table 138. Clydesdale Pharma Company Information Table 139. Clydesdale Pharma Business Overview Table 140. Clydesdale Pharma Frovatriptan Succinate Tablets Sales (k tablets), Revenue (US$ Million), Price (USD/k tablets) and Gross Margin (2021-2026) Table 141. Clydesdale Pharma Frovatriptan Succinate Tablets Product Portfolio Table 142. Clydesdale Pharma Recent Development Table 143. Glenmark Pharmaceuticals Company Information Table 144. Glenmark Pharmaceuticals Business Overview Table 145. Glenmark Pharmaceuticals Frovatriptan Succinate Tablets Sales (k tablets), Revenue (US$ Million), Price (USD/k tablets) and Gross Margin (2021-2026) Table 146. Glenmark Pharmaceuticals Frovatriptan Succinate Tablets Product Portfolio Table 147. Glenmark Pharmaceuticals Recent Development Table 148. Ingenus Pharmaceutical Company Information Table 149. Ingenus Pharmaceutical Business Overview Table 150. Ingenus Pharmaceutical Frovatriptan Succinate Tablets Sales (k tablets), Revenue (US$ Million), Price (USD/k tablets) and Gross Margin (2021-2026) Table 151. Ingenus Pharmaceutical Frovatriptan Succinate Tablets Product Portfolio Table 152. Ingenus Pharmaceutical Recent Development Table 153. North America Frovatriptan Succinate Tablets Market Size Growth Rate (CAGR) by Country (k tablets): 2021 VS 2025 VS 2032 Table 154. North America Frovatriptan Succinate Tablets Sales by Country (2021-2026) & (k tablets) Table 155. North America Frovatriptan Succinate Tablets Sales Market Share by Country (2021-2026) Table 156. North America Frovatriptan Succinate Tablets Sales Forecast by Country (2027-2032) & (k tablets) Table 157. North America Frovatriptan Succinate Tablets Sales Market Share Forecast by Country (2027-2032) Table 158. North America Frovatriptan Succinate Tablets Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 159. North America Frovatriptan Succinate Tablets Market Size by Country (2021-2026) & (US$ Million) Table 160. North America Frovatriptan Succinate Tablets Market Share by Country (2021-2026) Table 161. North America Frovatriptan Succinate Tablets Market Size Forecast by Country (2027-2032) & (US$ Million) Table 162. North America Frovatriptan Succinate Tablets Market Share Forecast by Country (2027-2032) Table 163. Europe Frovatriptan Succinate Tablets Market Size Growth Rate (CAGR) by Country (k tablets): 2021 VS 2025 VS 2032 Table 164. Europe Frovatriptan Succinate Tablets Sales by Country (2021-2026) & (k tablets) Table 165. Europe Frovatriptan Succinate Tablets Sales Market Share by Country (2021-2026) Table 166. Europe Frovatriptan Succinate Tablets Sales Forecast by Country (2027-2032) & (k tablets) Table 167. Europe Frovatriptan Succinate Tablets Sales Market Share Forecast by Country (2027-2032) Table 168. Europe Frovatriptan Succinate Tablets Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 169. Europe Frovatriptan Succinate Tablets Market Size by Country (2021-2026) & (US$ Million) Table 170. Europe Frovatriptan Succinate Tablets Market Share by Country (2021-2026) Table 171. Europe Frovatriptan Succinate Tablets Market Size Forecast by Country (2027-2032) & (US$ Million) Table 172. Europe Frovatriptan Succinate Tablets Market Share Forecast by Country (2027-2032) Table 173. Asia-Pacific Frovatriptan Succinate Tablets Market Size Growth Rate (CAGR) by Country (k tablets): 2021 VS 2025 VS 2032 Table 174. Asia-Pacific Frovatriptan Succinate Tablets Sales by Country (2021-2026) & (k tablets) Table 175. Asia-Pacific Frovatriptan Succinate Tablets Sales Market Share by Country (2021-2026) Table 176. Asia-Pacific Frovatriptan Succinate Tablets Sales Forecast by Country (2027-2032) & (k tablets) Table 177. Asia-Pacific Frovatriptan Succinate Tablets Sales Market Share Forecast by Country (2027-2032) Table 178. Asia-Pacific Frovatriptan Succinate Tablets Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 179. Asia-Pacific Frovatriptan Succinate Tablets Market Size by Country (2021-2026) & (US$ Million) Table 180. Asia-Pacific Frovatriptan Succinate Tablets Market Share by Country (2021-2026) Table 181. Asia-Pacific Frovatriptan Succinate Tablets Market Size Forecast by Country (2027-2032) & (US$ Million) Table 182. Asia-Pacific Frovatriptan Succinate Tablets Market Share Forecast by Country (2027-2032) Table 183. Latin America Frovatriptan Succinate Tablets Market Size Growth Rate (CAGR) by Country (k tablets): 2021 VS 2025 VS 2032 Table 184. Latin America Frovatriptan Succinate Tablets Sales by Country (2021-2026) & (k tablets) Table 185. Latin America Frovatriptan Succinate Tablets Sales Market Share by Country (2021-2026) Table 186. Latin America Frovatriptan Succinate Tablets Sales Forecast by Country (2027-2032) & (k tablets) Table 187. Latin America Frovatriptan Succinate Tablets Sales Market Share Forecast by Country (2027-2032) Table 188. Latin America Frovatriptan Succinate Tablets Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 189. Latin America Frovatriptan Succinate Tablets Market Size by Country (2021-2026) & (US$ Million) Table 190. Latin America Frovatriptan Succinate Tablets Market Share by Country (2021-2026) Table 191. Latin America Frovatriptan Succinate Tablets Market Size Forecast by Country (2027-2032) & (US$ Million) Table 192. Latin America Frovatriptan Succinate Tablets Market Share Forecast by Country (2027-2032) Table 193. Middle East and Africa Frovatriptan Succinate Tablets Market Size Growth Rate (CAGR) by Country (k tablets): 2021 VS 2025 VS 2032 Table 194. Middle East and Africa Frovatriptan Succinate Tablets Sales by Country (2021-2026) & (k tablets) Table 195. Middle East and Africa Frovatriptan Succinate Tablets Sales Market Share by Country (2021-2026) Table 196. Middle East and Africa Frovatriptan Succinate Tablets Sales Forecast by Country (2027-2032) & (k tablets) Table 197. Middle East and Africa Frovatriptan Succinate Tablets Sales Market Share Forecast by Country (2027-2032) Table 198. Middle East and Africa Frovatriptan Succinate Tablets Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 199. Middle East and Africa Frovatriptan Succinate Tablets Market Size by Country (2021-2026) & (US$ Million) Table 200. Middle East and Africa Frovatriptan Succinate Tablets Market Share by Country (2021-2026) Table 201. Middle East and Africa Frovatriptan Succinate Tablets Market Size Forecast by Country (2027-2032) & (US$ Million) Table 202. Middle East and Africa Frovatriptan Succinate Tablets Market Share Forecast by Country (2027-2032) Table 203. Key Raw Materials Table 204. Raw Materials Key Suppliers Table 205. Frovatriptan Succinate Tablets Distributors List Table 206. Frovatriptan Succinate Tablets Customers List Table 207. Research Programs/Design for This Report Table 208. Authors List of This Report Table 209. Secondary Sources Table 210. Primary Sources List of Figures Figure 1. Frovatriptan Succinate Tablets Image Figure 2. Global Frovatriptan Succinate Tablets Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Frovatriptan Succinate Tablets Market Size (2021-2032) & (US$ Million) Figure 4. Global Frovatriptan Succinate Tablets Sales (2021-2032) & (k tablets) Figure 5. Originator (RMP) Image Figure 6. Global Originator (RMP) Sales YoY Growth (2021-2032) & (k tablets) Figure 7. Originator-Licensed Brand Image Figure 8. Global Originator-Licensed Brand Sales YoY Growth (2021-2032) & (k tablets) Figure 9. Authorized Generic (AG) Image Figure 10. Global Authorized Generic (AG) Sales YoY Growth (2021-2032) & (k tablets) Figure 11. Conventional Generic Image Figure 12. Global Conventional Generic Sales YoY Growth (2021-2032) & (k tablets) Figure 13. Global Frovatriptan Succinate Tablets Market Size Overview by Type (2021-2032) & (US$ Million) Figure 14. Global Frovatriptan Succinate Tablets Market Share by Type 2025 VS 2032 Figure 15. North America Frovatriptan Succinate Tablets Sales Market Share in Volume by Type in 2025 Figure 16. North America Frovatriptan Succinate Tablets Sales Market Share in Value by Type in 2025 Figure 17. Europe Frovatriptan Succinate Tablets Sales Market Share in Volume by Type in 2025 Figure 18. Europe Frovatriptan Succinate Tablets Sales Market Share in Value by Type in 2025 Figure 19. Asia-Pacific Frovatriptan Succinate Tablets Sales Market Share in Volume by Type in 2025 Figure 20. Asia-Pacific Frovatriptan Succinate Tablets Sales Market Share in Value by Type in 2025 Figure 21. Latin America Frovatriptan Succinate Tablets Sales Market Share in Volume by Type in 2025 Figure 22. Latin America Frovatriptan Succinate Tablets Sales Market Share in Value by Type in 2025 Figure 23. Middle East and Africa Frovatriptan Succinate Tablets Sales Market Share in Volume by Type in 2025 Figure 24. Middle East and Africa Frovatriptan Succinate Tablets Sales Market Share in Value by Type in 2025 Figure 25. Global Top 5 and 10 Frovatriptan Succinate Tablets Players Market Share by Revenue in 2025 Figure 26. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. Hospital and Clinic Image Figure 28. Global Hospital and Clinic Sales YoY Growth (2021-2032) & (k tablets) Figure 29. Retail Pharmacies Image Figure 30. Global Retail Pharmacies Sales YoY Growth (2021-2032) & (k tablets) Figure 31. Other Image Figure 32. Global Other Sales YoY Growth (2021-2032) & (k tablets) Figure 33. Global Frovatriptan Succinate Tablets Market Size Overview by Application (2021-2032) & (US$ Million) Figure 34. Global Frovatriptan Succinate Tablets Market Share by Application 2025 VS 2032 Figure 35. North America Frovatriptan Succinate Tablets Sales Market Share in Volume by Application in 2025 Figure 36. North America Frovatriptan Succinate Tablets Sales Market Share in Value by Application in 2025 Figure 37. Europe Frovatriptan Succinate Tablets Sales Market Share in Volume by Application in 2025 Figure 38. Europe Frovatriptan Succinate Tablets Sales Market Share in Value by Application in 2025 Figure 39. Asia-Pacific Frovatriptan Succinate Tablets Sales Market Share in Volume by Application in 2025 Figure 40. Asia-Pacific Frovatriptan Succinate Tablets Sales Market Share in Value by Application in 2025 Figure 41. Latin America Frovatriptan Succinate Tablets Sales Market Share in Volume by Application in 2025 Figure 42. Latin America Frovatriptan Succinate Tablets Sales Market Share in Value by Application in 2025 Figure 43. Middle East and Africa Frovatriptan Succinate Tablets Sales Market Share in Volume by Application in 2025 Figure 44. Middle East and Africa Frovatriptan Succinate Tablets Sales Market Share in Value by Application in 2025 Figure 45. North America Frovatriptan Succinate Tablets Sales by Country: 2021 VS 2025 VS 2032 (k tablets) Figure 46. North America Frovatriptan Succinate Tablets Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. North America Frovatriptan Succinate Tablets Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. North America Frovatriptan Succinate Tablets Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Frovatriptan Succinate Tablets Sales by Country: 2021 VS 2025 VS 2032 (k tablets) Figure 50. Europe Frovatriptan Succinate Tablets Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe Frovatriptan Succinate Tablets Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Europe Frovatriptan Succinate Tablets Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific Frovatriptan Succinate Tablets Sales by Country: 2021 VS 2025 VS 2032 (k tablets) Figure 54. Asia-Pacific Frovatriptan Succinate Tablets Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Asia-Pacific Frovatriptan Succinate Tablets Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Asia-Pacific Frovatriptan Succinate Tablets Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Frovatriptan Succinate Tablets Sales by Country: 2021 VS 2025 VS 2032 (k tablets) Figure 58. Latin America Frovatriptan Succinate Tablets Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Latin America Frovatriptan Succinate Tablets Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Latin America Frovatriptan Succinate Tablets Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa Frovatriptan Succinate Tablets Sales by Country: 2021 VS 2025 VS 2032 (k tablets) Figure 62. Middle East and Africa Frovatriptan Succinate Tablets Sales Share by Country: 2021 VS 2025 VS 2032 Figure 63. Middle East and Africa Frovatriptan Succinate Tablets Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 64. Middle East and Africa Frovatriptan Succinate Tablets Market Share by Country: 2021 VS 2025 VS 2032 Figure 65. Frovatriptan Succinate Tablets Value Chain Figure 66. Key Raw Materials Price Figure 67. Manufacturing Cost Structure Figure 68. Frovatriptan Succinate Tablets Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Originator (RMP)
  • Originator-Licensed Brand
  • Authorized Generic (AG)
  • Conventional Generic
Applications
  • Hospital and Clinic
  • Retail Pharmacies
  • Other
Companies covered
  • Viatris
  • Teva
  • Endo Pharmaceuticals
  • Chia Tai Tianqing
  • HitGen
  • Accord（Intas）
  • Amneal Pharmaceuticals
  • Milpharm (Aurobindo)
  • Dr. Reddy’s
  • Sandoz
  • Zydus
  • Sun Pharma
  • Apotex
  • Clydesdale Pharma
  • Glenmark Pharmaceuticals
  • Ingenus Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Frovatriptan Succinate Tablets Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Frovatriptan Succinate Tablets Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Frovatriptan Succinate Tablets Market by Type
  6. 1.3.1 Originator (RMP)
  7. 1.3.2 Originator-Licensed Brand
  8. 1.3.3 Authorized Generic (AG)
  9. 1.3.4 Conventional Generic
  10. 1.4 Global Frovatriptan Succinate Tablets Market Size by Type
  11. 1.4.1 Global Frovatriptan Succinate Tablets Market Size Overview by Type (2021-2032)
  12. 1.4.2 Global Frovatriptan Succinate Tablets Historic Market Size Review by Type (2021-2026)
  13. 1.4.3 Global Frovatriptan Succinate Tablets Forecasted Market Size by Type (2027-2032)
  14. 1.5 Key Regions Market Size by Type
  15. 1.5.1 North America Frovatriptan Succinate Tablets Sales Breakdown by Type (2021-2026)
  16. 1.5.2 Europe Frovatriptan Succinate Tablets Sales Breakdown by Type (2021-2026)
  17. 1.5.3 Asia-Pacific Frovatriptan Succinate Tablets Sales Breakdown by Type (2021-2026)
  18. 1.5.4 South America Frovatriptan Succinate Tablets Sales Breakdown by Type (2021-2026)
  19. 1.5.5 Middle East and Africa Frovatriptan Succinate Tablets Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Frovatriptan Succinate Tablets Industry Trends
  2. 2.2 Frovatriptan Succinate Tablets Industry Drivers
  3. 2.3 Frovatriptan Succinate Tablets Industry Opportunities and Challenges
  4. 2.4 Frovatriptan Succinate Tablets Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Frovatriptan Succinate Tablets Revenue (2021-2026)
  2. 3.2 Global Top Players by Frovatriptan Succinate Tablets Sales (2021-2026)
  3. 3.3 Global Top Players by Frovatriptan Succinate Tablets Price (2021-2026)
  4. 3.4 Global Frovatriptan Succinate Tablets Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Frovatriptan Succinate Tablets Major Company Production Sites & Headquarters
  6. 3.6 Global Frovatriptan Succinate Tablets Company, Product Type & Application
  7. 3.7 Global Frovatriptan Succinate Tablets Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Frovatriptan Succinate Tablets Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Frovatriptan Succinate Tablets Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Frovatriptan Succinate Tablets Tier 1, Tier 2, and Tier 3
4 Frovatriptan Succinate Tablets Regional Status and Outlook
  1. 4.1 Global Frovatriptan Succinate Tablets Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Frovatriptan Succinate Tablets Historic Market Size by Region
  3. 4.2.1 Global Frovatriptan Succinate Tablets Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Frovatriptan Succinate Tablets Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Frovatriptan Succinate Tablets Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Frovatriptan Succinate Tablets Forecasted Market Size by Region
  7. 4.3.1 Global Frovatriptan Succinate Tablets Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Frovatriptan Succinate Tablets Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Frovatriptan Succinate Tablets Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Frovatriptan Succinate Tablets by Application
  1. 5.1 Frovatriptan Succinate Tablets Market by Application
  2. 5.1.1 Hospital and Clinic
  3. 5.1.2 Retail Pharmacies
  4. 5.1.3 Other
  5. 5.2 Global Frovatriptan Succinate Tablets Market Size by Application
  6. 5.2.1 Global Frovatriptan Succinate Tablets Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Frovatriptan Succinate Tablets Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Frovatriptan Succinate Tablets Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Frovatriptan Succinate Tablets Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Frovatriptan Succinate Tablets Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Frovatriptan Succinate Tablets Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Frovatriptan Succinate Tablets Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Frovatriptan Succinate Tablets Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Viatris
  2. 6.1.1 Viatris Company Information
  3. 6.1.2 Viatris Business Overview
  4. 6.1.3 Viatris Frovatriptan Succinate Tablets Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Viatris Frovatriptan Succinate Tablets Product Portfolio
  6. 6.1.5 Viatris Recent Developments
  7. 6.2 Teva
  8. 6.2.1 Teva Company Information
  9. 6.2.2 Teva Business Overview
  10. 6.2.3 Teva Frovatriptan Succinate Tablets Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Teva Frovatriptan Succinate Tablets Product Portfolio
  12. 6.2.5 Teva Recent Developments
  13. 6.3 Endo Pharmaceuticals
  14. 6.3.1 Endo Pharmaceuticals Company Information
  15. 6.3.2 Endo Pharmaceuticals Business Overview
  16. 6.3.3 Endo Pharmaceuticals Frovatriptan Succinate Tablets Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Endo Pharmaceuticals Frovatriptan Succinate Tablets Product Portfolio
  18. 6.3.5 Endo Pharmaceuticals Recent Developments
  19. 6.4 Chia Tai Tianqing
  20. 6.4.1 Chia Tai Tianqing Company Information
  21. 6.4.2 Chia Tai Tianqing Business Overview
  22. 6.4.3 Chia Tai Tianqing Frovatriptan Succinate Tablets Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Chia Tai Tianqing Frovatriptan Succinate Tablets Product Portfolio
  24. 6.4.5 Chia Tai Tianqing Recent Developments
  25. 6.5 HitGen
  26. 6.5.1 HitGen Company Information
  27. 6.5.2 HitGen Business Overview
  28. 6.5.3 HitGen Frovatriptan Succinate Tablets Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 HitGen Frovatriptan Succinate Tablets Product Portfolio
  30. 6.5.5 HitGen Recent Developments
  31. 6.6 Accord（Intas）
  32. 6.6.1 Accord（Intas） Company Information
  33. 6.6.2 Accord（Intas） Business Overview
  34. 6.6.3 Accord（Intas） Frovatriptan Succinate Tablets Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Accord（Intas） Frovatriptan Succinate Tablets Product Portfolio
  36. 6.6.5 Accord（Intas） Recent Developments
  37. 6.7 Amneal Pharmaceuticals
  38. 6.7.1 Amneal Pharmaceuticals Company Information
  39. 6.7.2 Amneal Pharmaceuticals Business Overview
  40. 6.7.3 Amneal Pharmaceuticals Frovatriptan Succinate Tablets Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Amneal Pharmaceuticals Frovatriptan Succinate Tablets Product Portfolio
  42. 6.7.5 Amneal Pharmaceuticals Recent Developments
  43. 6.8 Milpharm (Aurobindo)
  44. 6.8.1 Milpharm (Aurobindo) Company Information
  45. 6.8.2 Milpharm (Aurobindo) Business Overview
  46. 6.8.3 Milpharm (Aurobindo) Frovatriptan Succinate Tablets Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Milpharm (Aurobindo) Frovatriptan Succinate Tablets Product Portfolio
  48. 6.8.5 Milpharm (Aurobindo) Recent Developments
  49. 6.9 Dr. Reddy’s
  50. 6.9.1 Dr. Reddy’s Company Information
  51. 6.9.2 Dr. Reddy’s Business Overview
  52. 6.9.3 Dr. Reddy’s Frovatriptan Succinate Tablets Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Dr. Reddy’s Frovatriptan Succinate Tablets Product Portfolio
  54. 6.9.5 Dr. Reddy’s Recent Developments
  55. 6.10 Sandoz
  56. 6.10.1 Sandoz Company Information
  57. 6.10.2 Sandoz Business Overview
  58. 6.10.3 Sandoz Frovatriptan Succinate Tablets Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Sandoz Frovatriptan Succinate Tablets Product Portfolio
  60. 6.10.5 Sandoz Recent Developments
  61. 6.11 Zydus
  62. 6.11.1 Zydus Company Information
  63. 6.11.2 Zydus Business Overview
  64. 6.11.3 Zydus Frovatriptan Succinate Tablets Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Zydus Frovatriptan Succinate Tablets Product Portfolio
  66. 6.11.5 Zydus Recent Developments
  67. 6.12 Sun Pharma
  68. 6.12.1 Sun Pharma Company Information
  69. 6.12.2 Sun Pharma Business Overview
  70. 6.12.3 Sun Pharma Frovatriptan Succinate Tablets Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Sun Pharma Frovatriptan Succinate Tablets Product Portfolio
  72. 6.12.5 Sun Pharma Recent Developments
  73. 6.13 Apotex
  74. 6.13.1 Apotex Company Information
  75. 6.13.2 Apotex Business Overview
  76. 6.13.3 Apotex Frovatriptan Succinate Tablets Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 Apotex Frovatriptan Succinate Tablets Product Portfolio
  78. 6.13.5 Apotex Recent Developments
  79. 6.14 Clydesdale Pharma
  80. 6.14.1 Clydesdale Pharma Company Information
  81. 6.14.2 Clydesdale Pharma Business Overview
  82. 6.14.3 Clydesdale Pharma Frovatriptan Succinate Tablets Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 Clydesdale Pharma Frovatriptan Succinate Tablets Product Portfolio
  84. 6.14.5 Clydesdale Pharma Recent Developments
  85. 6.15 Glenmark Pharmaceuticals
  86. 6.15.1 Glenmark Pharmaceuticals Company Information
  87. 6.15.2 Glenmark Pharmaceuticals Business Overview
  88. 6.15.3 Glenmark Pharmaceuticals Frovatriptan Succinate Tablets Sales, Revenue and Gross Margin (2021-2026)
  89. 6.15.4 Glenmark Pharmaceuticals Frovatriptan Succinate Tablets Product Portfolio
  90. 6.15.5 Glenmark Pharmaceuticals Recent Developments
  91. 6.16 Ingenus Pharmaceutical
  92. 6.16.1 Ingenus Pharmaceutical Company Information
  93. 6.16.2 Ingenus Pharmaceutical Business Overview
  94. 6.16.3 Ingenus Pharmaceutical Frovatriptan Succinate Tablets Sales, Revenue and Gross Margin (2021-2026)
  95. 6.16.4 Ingenus Pharmaceutical Frovatriptan Succinate Tablets Product Portfolio
  96. 6.16.5 Ingenus Pharmaceutical Recent Developments
7 North America by Country
  1. 7.1 North America Frovatriptan Succinate Tablets Sales by Country
  2. 7.1.1 North America Frovatriptan Succinate Tablets Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Frovatriptan Succinate Tablets Sales by Country (2021-2026)
  4. 7.1.3 North America Frovatriptan Succinate Tablets Sales Forecast by Country (2027-2032)
  5. 7.2 North America Frovatriptan Succinate Tablets Market Size by Country
  6. 7.2.1 North America Frovatriptan Succinate Tablets Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Frovatriptan Succinate Tablets Market Size by Country (2021-2026)
  8. 7.2.3 North America Frovatriptan Succinate Tablets Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Frovatriptan Succinate Tablets Sales by Country
  2. 8.1.1 Europe Frovatriptan Succinate Tablets Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Frovatriptan Succinate Tablets Sales by Country (2021-2026)
  4. 8.1.3 Europe Frovatriptan Succinate Tablets Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Frovatriptan Succinate Tablets Market Size by Country
  6. 8.2.1 Europe Frovatriptan Succinate Tablets Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Frovatriptan Succinate Tablets Market Size by Country (2021-2026)
  8. 8.2.3 Europe Frovatriptan Succinate Tablets Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Frovatriptan Succinate Tablets Sales by Country
  2. 9.1.1 Asia-Pacific Frovatriptan Succinate Tablets Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Frovatriptan Succinate Tablets Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Frovatriptan Succinate Tablets Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Frovatriptan Succinate Tablets Market Size by Country
  6. 9.2.1 Asia-Pacific Frovatriptan Succinate Tablets Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Frovatriptan Succinate Tablets Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Frovatriptan Succinate Tablets Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Frovatriptan Succinate Tablets Sales by Country
  2. 10.1.1 South America Frovatriptan Succinate Tablets Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Frovatriptan Succinate Tablets Sales by Country (2021-2026)
  4. 10.1.3 South America Frovatriptan Succinate Tablets Sales Forecast by Country (2027-2032)
  5. 10.2 South America Frovatriptan Succinate Tablets Market Size by Country
  6. 10.2.1 South America Frovatriptan Succinate Tablets Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Frovatriptan Succinate Tablets Market Size by Country (2021-2026)
  8. 10.2.3 South America Frovatriptan Succinate Tablets Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Frovatriptan Succinate Tablets Sales by Country
  2. 11.1.1 Middle East and Africa Frovatriptan Succinate Tablets Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Frovatriptan Succinate Tablets Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Frovatriptan Succinate Tablets Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Frovatriptan Succinate Tablets Market Size by Country
  6. 11.2.1 Middle East and Africa Frovatriptan Succinate Tablets Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Frovatriptan Succinate Tablets Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Frovatriptan Succinate Tablets Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Frovatriptan Succinate Tablets Value Chain Analysis
  2. 12.1.1 Frovatriptan Succinate Tablets Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Frovatriptan Succinate Tablets Production Mode & Process
  7. 12.2 Frovatriptan Succinate Tablets Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Frovatriptan Succinate Tablets Distributors
  10. 12.2.3 Frovatriptan Succinate Tablets Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst